While studies have shown involvement of IL-17 pathways in the pathogenesis of PPP (7, 8), clinical trials investigating IL-17 blocking antibodies for the treatment of PPP have yielded conflicting results (9–11). This evidence concerns the gene IL17A and palmoplantar pustulosis.